IL2 and melanoma: In a phase III multicenter trial (NCT02278887) in the Netherlands, the median PFS of 84 patients receiving TIL (intravenous high-dose IL-2) treatment for unresectable advanced melanoma was significantly higher than that of ipilimumab treatment (7.2 months vs. 3.1 months, p < 0.001), but the incidence of treatment-related AEs also increased (54).